This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kiska, D. L. Articles by Gilligan, P. H. Search for Related Content PubMed PubMed Citation Articles by Kiska, D. L. Articles by Gilligan, P. H.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 1995, 1141-1144, Vol 33, No. 5
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Quality assurance study of bacterial antigen testing of cerebrospinal fluid

DL Kiska, MC Jones, ME Mangum, D Orkiszewski and PH Gilligan
Clinical Microbiology and Immunology Laboratories, University of North Carolina Hospital 27514, USA.

Bacterial antigen testing (BAT) of cerebrospinal fluid (CSF) by latex agglutination is a low-yield procedure in patients whose CSF specimens have normal laboratory parameters. Between August 1992 and August 1994, we evaluated 287 bacterial antigen (BA) test requests to determine whether yields could be improved and whether patient costs could be reduced by cancelling BAT for those patients with normal CSF parameters (cell count, protein, glucose) after consultation with physicians. A total of 171 (68%) BA tests were canceled by this approach. None of these CSF specimens was culture positive for an organism detectable by BAT. Of the remaining 116 CSF specimens tested, only 3 were positive by BAT, one each for Neisseria meningitidis, Streptococcus pneumoniae, and group B streptococcus. Only 43 of the CSF specimens tested had at least two abnormal parameters; the 3 positive CSF specimens were included in this group. In light of the low rate of positivity, the number of BA tests can be further reduced by establishing criteria that must be met before a CSF specimen is accepted for BAT. After review of our data and the literature concerning this topic, we concluded that only specimens with leukocyte counts of > or = 50 cells per mm3 should be tested. Of 287 specimens evaluated in our study, only 36 met this criterion, including the 3 BA-positive specimens. Enacting such a restriction would have reduced the total number of BA tests by 251 (87%) without compromising patient care. A laboratory cost savings of $6,500 per year would have been realized, with a substantial reduction in the cost per positive test.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

• Nachamkin, I., Zunkeler, B., Chaudhuri, A., Behan, P. O., Young, A. B., Vartanian, T. (1999). Case 1-1999: Acute Hemorrhagic Leukoencephalitis. NEJM 341: 1314-1316 [Full Text]